Allelic variations in angiogenic pathway genes are associated with preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 5, 2010, Pages 445.e1-445.e11

  Srinivas, Sindhu K ^a   Morrison, Alanna C ^b   Andrela, Christina M ^a   Elovitz, Michal A ^a  

^a Center for Research on Reproduction and Women's Health   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

angiogenesis; gene; preeclampsia; sFlt

Indexed keywords

DNA; ENDOGLIN; FMS LIKE TYROSINE KINASE 1; FMS LIKE TYROSINE KINASE 4; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C;

ADULT; AGE DETERMINATION; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEGRO; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77951878033     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.01.040     Document Type: Article

References (37)

1. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
2. Centers for Disease Control. Morbidity and mortality weekly report: pregnancy-related mortality surveillance-United States, 1991-1999. CDC MMWR 52 (2003) SS-2
3. Roberts J.M., and Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 357 (2001) 53-56
4. Wang Y., Gu Y., Zhang Y., and Lewis D.F. Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol 190 (2004) 817-824
5. Redman C.W. Current topic: pre-eclampsia and the placenta. Placenta 12 (1991) 301-308
6. Robertson S.A., Ingman W.V., O'Leary S., Sharkey D.J., and Tremellen K.P. Transforming growth factor beta: a mediator of immune deviation in seminal plasma. J Reprod Immunol 57 (2002) 109-128
7. Redman C.W., Sacks G.P., and Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180 (1999) 499-506
8. Catov J.M., Ness R.B., Kip K.E., and Olsen J. Risk of early or severe pre-eclampsia related to pre-existing conditions. Int J Epidemiol 36 (2007) 412-419
9. Bodnar L.M., Ness R.B., Markovic N., and Roberts J.M. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol 15 (2005) 475-482
10. Diagnosis and management of preeclampsia and eclampsia. In: American College of Obstetricians and Gynecologists Compendium 2008: practice bulletin, no. 33;2002;2002.
11. Campbell D.M., MacGillivray I., and Carr-Hill R. Pre-eclampsia in second pregnancy. BJOG 92 (1985) 131-140
12. Dildy III G.A., Belfort M.A., and Smulian J.C. Preeclampsia recurrence and prevention. Semin Perinatol 31 (2007) 135-141
13. Cnattingius S., Reilly M., Pawitan Y., and Lichtenstein P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet A 130A (2004) 365-371
14. Dawson L.M., Parfrey P.S., Hefferton D., et al. Familial risk of preeclampsia in Newfoundland: a population-based study. J Am Soc Nephrol 13 (2002) 1901-1906
15. Ness R.B., Markovic N., Bass D., Harger G., and Roberts J.M. Family history of hypertension, heart disease, and stroke among women who develop hypertension in pregnancy. Obstet Gynecol 102 (2003) 1366-1371
16. Lachmeijer A., Dekker G., Pals G., Aarnoudse J., Kate L., and Arngrimsson R. Searching for preeclampsia genes: the current position. Eur J Obstet Gynecol Reprod Biol 105 (2002) 94-113
17. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
18. Salahuddin S., Lee Y., Vadnais M., Sachs B.P., Karumanchi S.A., and Lim K.H. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 197 (2007) 28.e1-6
19. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50 (2007) 137-142
20. Moore Simas T.A., Crawford S.L., Solitro M.J., Frost S.C., Meyer B.A., and Maynard S.E. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 197 (2007) 244.e1-8
21. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21 (2008) 9-23
22. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
23. Edlow A., Srinivas S., and Elovitz M. Investigating the risk of hypertension shortly after pregnancies complicated by preeclampsia. Am J Obstet Gynecol 200 (2009) e60-e62
24. Mazar R., Srinivas S., Sammel M., Andrela C., and Elovitz M. Metabolic score as a novel approach to assessing preeclampsia risk. Am J Obstet Gynecol 197 (2007) 411.e1-5
25. Srinivas S.K., Edlow A.G., Neff P.M., Sammel M.D., Andrela C.M., and Elovitz M.A. Rethinking IUGR in preeclampsia: dependent or independent of maternal hypertension. J Perinatol 29 (2009) 680-684
26. Srinivas S.K., Sammel M.D., Bastek J., et al. Evaluating the association between all components of the metabolic syndrome and pre-eclampsia. J Matern Fetal Neonatal Med 22 (2009) 501-509
27. Keating B., Tischfield S., Murray S., et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 3 (2008) e3583
28. Purcell S., Neale B., Todd-Brown K., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 (2007) 559-575
29. Excoffier L., and Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12 (1995) 921-927
30. Mathias R.A., Gao P., Goldstein J.L., et al. A graphical assessment of p-values from sliding window haplotype tests of association to identify asthma susceptibility loci on chromosome 11q. BMC Genet 7 (2006) 38
31. Shibata E., Rajakumar A., Powers R.W., et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90 (2005) 4895-4903
32. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
33. Chedraui P., Lockwood C.J., Schatz F., et al. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. J Matern Fetal Neonatal Med (2009) 565-570
34. Rogers M.S., and D'Amato R.J. The effect of genetic diversity on angiogenesis. Exp Cell Res 312 (2006) 561-574
35. Papazoglou D., Galazios G., Koukourakis M.I., et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 10 (2004) 321-324
36. Sitras V., Paulssen R.H., Gronaas H., et al. Differential placental gene expression in severe preeclampsia. Placenta 30 (2009) 424-433
37. Kim S.Y., Lim J.H., Yang J.H., et al. Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia. BMC Med Genet 9 (2008) 68